How many drugs treat Magnetic resonance imaging?

Drug Landscape tracks 9 marketed treatments for Magnetic resonance imaging (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/magnetic-resonance-imaging.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Magnetic resonance imaging — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnetic resonance imaging (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Magnetic resonance imaging, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	First approval
Dotarem	GADOTERATE MEGLUMINE	Guerbet	gadoterate meglumine	2013-01-01
Gadavist	GADOBUTROL	Bayer	Gadolinium-based Contrast Agent [EPC]	2011-01-01
Optimark	GADOVERSETAMIDE	Liebel-Flarsheim	Paramagnetic Contrast Agent	1999-01-01
Gastromark	FERUMOXSIL	Amag Pharms Inc		1996-01-01
Omniscan	GADODIAMIDE	GE HealthCare	Paramagnetic Contrast Agent [EPC]	1993-01-01
Omniscan	Omniscan	GE Healthcare
Gadoterate	Gadoterate	Loyola University
Gadovist	Gadovist	Vanderbilt University Medical Center
Gadavist	Gadavist	Brigham and Women's Hospital

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amag Pharms Inc · 1 drug in Magnetic resonance imaging
Bayer · 1 drug in Magnetic resonance imaging
Brigham and Women's Hospital · 1 drug in Magnetic resonance imaging
GE HealthCare · 1 drug in Magnetic resonance imaging
GE Healthcare · 1 drug in Magnetic resonance imaging
Guerbet · 1 drug in Magnetic resonance imaging
Liebel-Flarsheim · 1 drug in Magnetic resonance imaging
Loyola University · 1 drug in Magnetic resonance imaging
Vanderbilt University Medical Center · 1 drug in Magnetic resonance imaging

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Magnetic resonance imaging:

Cite this brief

Drug Landscape (2026). Magnetic resonance imaging — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/magnetic-resonance-imaging. Accessed 2026-06-10.

Magnetic resonance imaging full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing